Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.

Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, Delaporte E, Messou E, McIntyre J, El Filali KM, Schechter M, Kumarasamy N, Bangsberg D, McPhail P, Van Der Borght S, Zala C, Egger M, Thiébaut R, Dabis F; T-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa).

BMC Infect Dis. 2012 Jun 28;12:147. doi: 10.1186/1471-2334-12-147.

2.

CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.

Hoffmann CJ, Schomaker M, Fox MP, Mutevedzi P, Giddy J, Prozesky H, Wood R, Garone DB, Egger M, Boulle A; IeDEA Southern Africa Collaboration.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):34-41. doi: 10.1097/QAI.0b013e318287c1fe.

3.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
4.

A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.

Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, Jahed NC, Jacobson JM, Myers LS, Schmitz JL, Winters M, Tebas P; A5102 Study Team of the AIDS Clinical Trials Group.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):140-8.

PMID:
16760795
5.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
6.

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.

PMID:
18783328
7.

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, Taburet AM, Balkan S, Olson DM, Olaro C, Pujades-Rodríguez M.

BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.

8.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
9.

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

JAMA. 2001 Nov 28;286(20):2560-7.

PMID:
11722270
10.

Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.

Achhra AC, Phillips A, Emery S, MacArthur RD, Furrer H, De Wit S, Losso M, Law MG; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Management of Antiretroviral Therapy (SMART) and Flexible Initial Retrovirus Suppressive Therapies (FIRST) study groups.

HIV Med. 2015 Aug;16(7):449-54. doi: 10.1111/hiv.12258. Epub 2015 May 11.

PMID:
25959989
11.

Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.

Wandeler G, Gsponer T, Mulenga L, Garone D, Wood R, Maskew M, Prozesky H, Hoffmann C, Ehmer J, Dickinson D, Davies MA, Egger M, Keiser O; IeDEA Southern Africa Collaboration.

AIDS. 2013 Sep 10;27(14):2225-32. doi: 10.1097/QAD.0b013e328362d887.

12.

Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.

Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwan W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S; TREAT Asia HIV Observational Databases (TAHOD); TREAT Asia Studies to Evaluate Resistance (TASER).

J Int AIDS Soc. 2014 Mar 14;17:18804. doi: 10.7448/IAS.17.1.18804. eCollection 2014.

13.

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.

Byakwaga H, Murray JM, Petoumenos K, Kelleher AD, Law MG, Boyd MA, Emery S, Mallon PW, Cooper DA.

AIDS Res Hum Retroviruses. 2009 Jun;25(6):756-76. doi: 10.1089/aid.2008.0149.

PMID:
19500017
14.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
15.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.

PMID:
16007534
16.

Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.

Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R; ANRS 12-06/IMEA 012 Trial Study Group.

MedGenMed. 2007 Oct 9;9(4):7.

17.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
18.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

19.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
20.

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT.

Clin Infect Dis. 2013 Nov;57(10):1483-8. doi: 10.1093/cid/cit538. Epub 2013 Aug 13.

Supplemental Content

Support Center